Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19
Complement, a critical defence against pathogens, has been implicated as a driver of pathology in COVID-19. Complement activation products are detected in plasma and tissues and complement blockade considered for therapy. To delineate roles of complement in immunopathogenesis, we undertook the large...
Үндсэн зохиолчид: | Siggins, M, Davies, K, Fellows, R, Thwaites, R, Baillie, K, Semple, M, Openshaw, P, Zelek, W, Harris, CL, Morgan, BP, Dunning, W |
---|---|
Бусад зохиолчид: | The ISARIC4C Investigators |
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Wiley
2022
|
Ижил төстэй зүйлс
-
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
-н: Wioleta M. Zelek, зэрэг
Хэвлэсэн: (2020-12-01) -
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
-н: Sarah M. Carpanini, зэрэг
Хэвлэсэн: (2022-07-01) -
Dysregulation of complement system in HELLP syndrome
-н: Shi Chen, зэрэг
Хэвлэсэн: (2021-10-01) -
Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway
-н: Wioleta Zelek
Хэвлэсэн: (2021-10-01) -
Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study
-н: Amer Toutonji, зэрэг
Хэвлэсэн: (2021-07-01)